Abstract
Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Current Drug Targets
Title:Proteomic Classification of Breast Cancer
Volume: 13 Issue: 12
Author(s): Dalia Kamel, Bernadette Brady, Adel Tabchy, Gordon B. Mills and Bryan Hennessy
Affiliation:
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Abstract: Being a significant health problem that affects patients in various age groups, breast cancer has been extensively studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme- linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic classification of breast cancer.
Export Options
About this article
Cite this article as:
Kamel Dalia, Brady Bernadette, Tabchy Adel, B. Mills Gordon and Hennessy Bryan, Proteomic Classification of Breast Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530080
DOI https://dx.doi.org/10.2174/138945012803530080 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Fatty Acid Amide Hydrolase Inhibitors – Progress and Potential
CNS & Neurological Disorders - Drug Targets The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Mediterranean Dietary Traditions for the Molecular Treatment of Human Cancer: Anti-Oncogenic Actions of the Main Olive Oils Monounsaturated Fatty Acid Oleic Acid (18:1n-9)
Current Pharmaceutical Biotechnology Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Subject Index To Volume 7
Current Drug Targets Anti-inflammatory Effects of Rosuvastatin in Healthy Subjects: A Prospective Longitudinal Study
Current Pharmaceutical Design Pegylated Naloxone in the Treatment of Persistent Opioid-Induced Constipation in Patients with Hematological Malignancies
Cardiovascular & Hematological Agents in Medicinal Chemistry Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Multi-Kinase Inhibitors
Current Medicinal Chemistry Fibrinolytic Protease from Marine Streptomyces rubiginosus VITPSS1
Cardiovascular & Hematological Agents in Medicinal Chemistry The Effects of 1,3,5-trisubstituted Indole Derivatives on Cell Growth, Apoptosis and MMP-2/9 mRNA Expression of MCF-7 Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Drug Targets Discrepant mRNA and Protein Expression in Immune Cells
Current Genomics Cancer Diagnosis and Disease Gene Identification <i>via</i> Statistical Machine Learning
Current Bioinformatics Pleiotropic Effects of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors: Candidate Mechanisms for Anti-Lipid Deposition in Blood Vessels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System
Protein & Peptide Letters